LTRN Lantern Pharma Inc.

Biotech Analyst Ratings

Latest News

1. 12 May 2022 Lantern Pharma to Host Virtual KOL Event on Glioblastoma Multiforme (GBM) with Collaborators from Johns Hopkins during Brain Tumor Awareness Month

   View Full Article
2. 05 May 2022 Lantern Pharma Management to Speak at Multiple Investor and Scientific Conferences in May 2022

   Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR^® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the Company's management will be speaking at five investor and scientific conferences in May 2022.

   Dr. Kishor Bhatia, Lantern's Chief Scientific Officer, will be speaking at the 9^th Drug Discovery Strategic Summit on May 9^th, and presenting on the synthetic lethality potential of Lantern's drug candidates. Additionally, Panna Sharma, Lantern's Chief Executive Officer and President, will be speaking at four events in May, including the Strategic Investment Conference…

   View Full Article
3. 03 May 2022 Lantern Pharma Reports First Quarter 2022 Financial Results and Operational Highlights

   • RADR^®, Lantern's proprietary A.I. and machine learning platform, has now surpassed 20 billion data points, enhancing its precision, insights, and capabilities for oncology drug discovery
   • Launch and enrollment of the HARMONIC™ clinical trial expected in Summer of 2022; the Phase 2 trial is for LP-300 in never-smokers with lung cancer
   • IND application for LP-184 targeted for submission with the FDA in Q3 2022; enabling a first in-human clinical trial for genomically defined solid tumors
   • Announced brain metastases as a new indication being pursued for LP-184 at the American Association of Cancer Research annual meeting
   • Advanced preclinical studies are underway in Australia, through Australian subsidiary, Lantern Pharma Australia Pty Ltd., to take advantage…

   View Full Article
4. 26 April 2022 Lantern Pharma's Board of Directors Names Maria Maccecchini, Ph.D. as a Director Nominee to Lantern's Board of Directors

   View Full Article
5. 22 April 2022 Lantern Pharma to Report First Quarter 2022 Operating & Financial Results on May 3rd, 2022 at 4:30 p.m. ET

   View Full Article